# A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

> **NCT05689151** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 183 (estimated)

## Conditions studied

- Atopic Dermatitis
- Eczema

## Interventions

- **DRUG:** Abrocitinib

## Key facts

- **NCT ID:** NCT05689151
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2026-06-05
- **Final completion:** 2027-12-31
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689151, "A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05689151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*